Literature DB >> 29409398

Immune dysregulation in primary immune thrombocytopenia patients.

Jiakui Zhang1, Qiuye Zhang1, Yingwei Li1, Lili Tao1, Fan Wu1, Yuanyuan Shen1, Qianshan Tao1, Xuanxuan Xu1, Can Wu1, Yanjie Ruan1, Jiyu Wang1, Jeffrey Wang2, Yiping Wang2, Zhimin Zhai1.   

Abstract

OBJECTIVES: To explore the immunological abnormalities in patients with primary immune thrombocytopenia (ITP), and analyze its relationship with treatment.
METHODS: Proportion of different immune cell subsets were detected in the peripheral blood of 124 ITP patients at different time points and 45 normal controls by flow cytometry. The treatments included glucocorticoids, intravenous IgG as first-line treatment and second-line drugs.
RESULTS: Elevated CD4/CD8 ratio and decreased the proportion of NK and CD4 + CD25 + CD127low regulatory T cells (Tregs) were found in pre-treated ITP patients than healthy controls. The newly diagnosed group had a significantly higher CD4/CD8 ratio than the relapsed group, but no differences in the proportion of B cells, NK cells and Tregs. No relationships were found between the curative effect and the pre-treated cell subsets within both the effective and ineffective groups. Furthermore, compared with the ineffective group, the effective group had higher Tregs and lower CD4/CD8 ratio post-treatment, but no significant differences in NK and B cells.
CONCLUSION: ITP patients presented with a high CD4/CD8 ratio and low levels of Tregs and NK cells, suggesting that immune deregulation was involved in the pathogenesis of ITP. The pre-treated immune status of ITP patients may not be related to the curative effect. Tregs significantly increased in the effective group post-treatment, highlighting that the mechanism of restoring Tregs may be involved in the treatment of ITP. However, whether or not the targeted regulation of Tregs is an effective treatment for ITP still requires further studies.

Entities:  

Keywords:  Immune thrombocytopenia; cellular immunity; pathogenesis; regulatory T cells; treatment

Mesh:

Year:  2018        PMID: 29409398     DOI: 10.1080/10245332.2018.1435021

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  3 in total

1.  Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

Authors:  Furun An; Huiping Wang; Zhenyun Liu; Fan Wu; Jiakui Zhang; Qianshan Tao; Yingwei Li; Yuanyuan Shen; Yanjie Ruan; Qing Zhang; Ying Pan; Weiwei Zhu; Hui Qin; Yansheng Wang; Yongling Fu; Zhenqing Feng; Zhimin Zhai
Journal:  Nat Commun       Date:  2020-11-23       Impact factor: 14.919

Review 2.  Immunomodulatory cytokine interleukin-35 and immune thrombocytopaenia.

Authors:  Jing-Jing Zhu; Ning-Ning Shan
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

3.  Diagnostic Value of Peripheral Blood Lymphocytes for Primary Immune Thrombocytopenia.

Authors:  Jun Lu; Ling Sun; Xifeng Wu; Tantan Li; Lijie Men
Journal:  Contrast Media Mol Imaging       Date:  2022-08-16       Impact factor: 3.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.